Rockwell Medical, Inc.
Rockwell Medical, Inc.
Your view on RMTI
Overview
What the company does, where it operates, and who runs it.
About Rockwell Medical, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mark Strobeck
- Headquarters
- 30142 South Wixom road, Wixom, MI, US
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mark Strobeck
- Headquarters
- 30142 South Wixom road, Wixom, MI, US
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally.
The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores.
It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers.
The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream.
It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home.
Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Rockwell Medical, Inc. from FRC's valuation model, read against the market price. RMTI last traded at $7.03; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Rockwell Medical, Inc.. Starting points for Rockwell Medical, Inc.: EPS -$1.42, beta 1.73 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Rockwell Medical, Inc.. Rockwell Medical, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Rockwell Medical, Inc.. Trailing twelve-month EPS for Rockwell Medical, Inc. stands at -$1.42. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$20.00
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy10
- Hold2
- Sell4
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.43 | -$0.25 | -$1.51 | -$0.73 |
| Low estimate | -$0.44 | -$0.25 | -$1.53 | -$0.74 |
| High estimate | -$0.42 | -$0.25 | -$1.49 | -$0.72 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$0.101 | -$0.401 | -$1.501 | — |
| Growth | — | — | — | — |
1Year-ago EPS includes one-time items; growth not shown.
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $19.00M | $18.85M | $72.78M | $78.62M |
| Low estimate | $18.81M | $18.66M | $72.09M | $77.87M |
| High estimate | $19.20M | $19.04M | $73.48M | $79.37M |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago revenue | $18.35M | $17.34M | $69.26M | — |
| Growth | +3.6% | +8.7% | +5.1% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 16, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Rockwell Medical, Inc.. Rockwell Medical, Inc. has reported as a listed company since 1998. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- APUSApimeds Pharmaceuticals US, IncBiotechnology$3M
- ATHEAlterity Therapeutics LimitedBiotechnology$31M
- CPIXCumberland Pharmaceuticals Inc.Drug Manufacturers - Specialty & Generic$88M
- EVAXEvaxion Biotech A/SBiotechnology$17M
- LIMNLiminatus Pharma, Inc. Class A Common StockBiotechnology$4M
- NMTCNeuroOne Medical Technologies CorporationMedical - Devices$7M
- QNTMQuantum BioPharma Ltd.Biotechnology$10M
More Drug Manufacturers - Specialty & Generic companies
- IPSEYIpsen S.A.OTC$61.0B
- IRWDIronwood Pharmaceuticals, Inc.NASDAQ$800M
- ISCNFIsracann Biosciences Inc.OTC$1,982
- ISOLFIsodiol International Inc.OTC$4,914
- ITHUFiAnthus Capital Holdings, Inc.OTC$34M
- IVIXFInvion LimitedOTC$3M
- IVX.AXInvion LimitedASX
- JUSH.CNJushi Holdings Inc.CNQ$165M
- JUVAFJuva Life Inc.OTC$1,641
- JWCAFJames E. Wagner Cultivation CorporationOTC$10,942
- KALYKali, Inc.OTC$50,912
- KAYSKaya Holdings, Inc.OTC
ETFs holding Rockwell Medical, Inc.
% of the fund
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
- VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
- VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%
- VBAL.TOVanguard Balanced ETF Portfolio$6.0B in assets0.00%
- VUS.TOVanguard U.S. Total Market Index ETF (CAD-hedged)$1.4B in assets0.00%
Largest holders first, then the funds most concentrated in RMTI.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Rockwell Medical, Inc., and how their positions are changing. At a $28.3M market value, institutional positions materially move Rockwell Medical, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Rockwell Medical, Inc. executives and directors. Shares of Rockwell Medical, Inc. have traded between $0.78 and $2.52 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Rockwell Medical, Inc.. Coverage tracks Rockwell Medical, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Rockwell Medical, Inc.